Challenges and successes in developing new therapies for hepatitis C

Raffaele De Francesco () and Giovanni Migliaccio
Additional contact information
Raffaele De Francesco: Istituto di Ricerche di Biologia Molecolare P. Angeletti
Giovanni Migliaccio: Istituto di Ricerche di Biologia Molecolare P. Angeletti

Nature, 2005, vol. 436, issue 7053, 953-960

Abstract: Abstract Hepatitis C virus (HCV) will continue to be a serious global health threat for many years to come because of the chronic nature of the infection, its high prevalence and the significant morbidity of the resulting disease. Recently, a small number of molecules have produced encouraging results in proof-of-concept clinical trials. At the same time, preclinical evidence is accumulating that development of resistance will eventually limit the efficacy of new drugs. Thus, combinations of multiple agents will be required to treat chronic HCV infection.

Date: 2005
References: Add references at CitEc
Citations: View citations in EconPapers (1)

Downloads: (external link)
https://www.nature.com/articles/nature04080 Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:nature:v:436:y:2005:i:7053:d:10.1038_nature04080

Ordering information: This journal article can be ordered from
https://www.nature.com/

DOI: 10.1038/nature04080

Access Statistics for this article

Nature is currently edited by Magdalena Skipper

More articles in Nature from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().